tiprankstipranks
Trending News
More News >

Omada Health initiated with an Overweight at Barclays

Barclays initiated coverage of Omada Health (OMDA) with an Overweight rating and $21 price target. Omada’s digital health solution is addressing a large market given the prevalence of prediabetes, diabetes, hypertension and musculoskeletal issues, says the analyst, who thinks the company’s GLP-1 Care Track offerings could be an accelerant to adoption. The firm thinks Omada is gaining share in this cardiometabolic market, particularly from Teladoc’s (TDOC) Livongo, the analyst added.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1